Nine of 11 advisory panel members found that data did not support MDMA-assisted therapy effectiveness for PTSD, citing concerns over missing safety data and unclear drug vs. psychotherapy effects.
Despite some expressing support, panel members highlighted doubts due to insufficient evidence and belief that it's premature to approve MDMA treatment for PTSD.
Advocates urge approval due to limited effective treatments for PTSD patients. Panel acknowledges challenges, including concerns over data integrity and treatment efficacy.
[
Collection
]
[
|
...
]